Medication-related AI commonly focuses on drug interactions, prescription optimisation, adverse event prediction and medication adherence.
However, an important factor is often overlooked: can the patient afford the medication?
A patient may understand the prescription and be willing to follow treatment but still be unable to purchase the medicine.
This presents an opportunity for healthcare data science.
1. Define the affordability problem
Medication affordability can be influenced by medicine prices, insurance coverage, household income, geographical availability and recurring treatment expenses.
A missed refill does not necessarily mean intentional non-adherence.
A system should distinguish between observed medication access patterns and the underlying reasons for them.
2. Potential data sources
A medication affordability intelligence system could use verified medicine pricing, relevant insurance coverage, dispensing and refill records, patient-reported financial barriers and medicine availability information.
These sources should be linked responsibly, with appropriate consent, privacy controls and data governance.
3. A possible AI workflow
A system could identify a patient whose medication refill has been delayed.
Rather than automatically classifying the event as non-adherence, it could check available information for potential affordability barriers.
Where relevant data is unavailable, the system should ask for clarification or recommend a conversation with a healthcare professional.
It could then prepare a report showing verified cost information and possible assistance pathways.
4. Why clinical constraints matter
Cost optimisation cannot operate independently of clinical suitability.
A cheaper medicine may have different contraindications, interactions, formulations or dosing requirements.
Any proposed alternative must undergo appropriate professional review.
For agentic AI, comparing prices and preparing recommendations may be permitted, while changing a prescription requires properly governed clinical authority.
5. Evaluation considerations
Useful evaluation measures include affordability barrier identification accuracy, reliability of price information, referral appropriateness, patient access outcomes and changes in avoidable treatment interruptions.
Researchers should also assess performance across income groups and healthcare settings.
Conclusion
Medication affordability is not simply an economic consideration. It can directly influence whether treatment is accessible and sustainable.
Healthcare AI should therefore move beyond identifying what medication a patient needs and consider whether the patient can realistically obtain it.
If you are developing healthcare AI, pharmacy analytics or medication management systems, consider affordability intelligence as an important component of patient-centred care.